And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest this time around. We plan to hang with Mrs. Pharmalot, catch up on some reading, and putter around the castle. And what about you? This remains a lovely time to enjoy the great outdoors. After all, the Great Pumpkin beckons. You could also take in a moving picture or search for a good novel. Perhaps this is also a good time to stock up on items from China before tariffs take more of a bite. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Sanofi (SNY) won a victory over its controversial dengue vaccine as a European Medicines Agency committee recommended Dengvaxia for use in Europe for people 9 years or older. The move follows a year-long scandal in the Philippines after the drug maker disclosed its vaccine can worsen rather than prevent future cases in people who were not previously exposed to the mosquito-borne virus. The circumstances were unique, but caused public confidence in vaccines to plummet in the country and offered a cautionary tale for addressing unexpected concerns about vaccines.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy